Russian Federation says its Sputnik V Covid-19 vaccine is 95% effective

Cheryl Sanders
November 24, 2020

The statement emphasized that Russian citizens will receive the vaccine free of charge.

Russian Federation plans to start mass vaccination against the coronavirus in 2021, Deputy Prime Minister Tatyana Golikova, who is overseeing Russia's Covid-19 response, said earlier Tuesday.

The Kremlin said on Tuesday that President Vladimir Putin had yet to be vaccinated with Sputnik V. His position meant he could not take something that was still being trialled, it said.

The pricing announcement comes as Russian Federation looks to scale up distribution and production.

The global market price for Sputnik V unveiled on Tuesday is cheaper than some other Western rivals such as a vaccine produced by Pfizer-BioNTech, which costs 15.5 euros per shot, but more expensive that a vaccine produced by AstraZeneca which will be sold in Europe for around 2.5 euros per shot.


It said it was basing its assessment on mRNA vaccines where pricing had already been announced and interim phase three clinical trials were underway.

The Oxford-AstraZeneca adenovirus-based vaccine candidate was reported on Monday to have an efficacy of 70% and Pfizer-BioNtech and Moderna's m-RNA vaccines reported efficacy rates in the low 90s. Current agreements between RDIF and leading foreign pharmaceutical companies allow production of the vaccine overseas for 500 million people per year starting from 2021. The vaccine supplies for the global market will be produced by RDIF's worldwide partners in India, Brazil, China, South Korea and other countries.

The RDIF is also looking into additional orders made by some countries and companies to increase the production of the vaccine.

Talks were also ongoing with other foreign partners on increasing production, he added.

Gamaleya Center and Russia's sovereign wealth fund RDIF on November 24 announced that their coronavirus vaccine Sputnik V has demonstrated 91.4 percent efficacy in preventing COVID-19 infection in the second interim analysis on day 28 after the first dose, and over 95 percent following 21 days after the second dose in phase-3 trials.


On Sunday, high-level central teams were deputed to Uttar Pradesh, Punjab and Himachal Pradesh to support them in Covid-19 response and management.

A researcher works inside a laboratory of the Gamaleya Scientific Research Institute of Epidemiology and Microbiology where the world's first coronavirus vaccine registered in Russia was developed, in Moscow, Russia.

Russian Federation has denied that, alleging a Western dirty tricks campaign to put people off its vaccine in what it believes has become a battle for legitimacy and market share.

Russia's announcement in August that it had found a vaccine candidate both shocked and excited the world, but was promptly met with criticism and concerns over transparency.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER